Patent SG-11201903106Q-A (SG)
Title: Treatment regimens
Inventor: ROLLINS SCOTT
IPC: A61P7/00
Filed: 2017-11-03
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property MD HIM 0 11101 HOE 3E1 0 01111E1111M 100 HE EMI ill 011 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\"\"1 WO 2018/083645 Al 11 May 2018 (11.05.2018) WIPO I PCT — (51) (21) (22) (25) Filing Language: (26) (30) (71) (72) International Patent Classification: Oklahoma 73104 (US). BRUEDERLE, Andreas; c/o No- A61K 39/395 (2006.01) A61P 7/00 (2006.01) vartis Pharma AG, Postfach, 4002 Basel (CH). CO7K 16/28 (2006.01) (81) Designated States (unless otherwise indicated, for every International Application Number: kind of national protection available): AE, AG, AL, AM, PCT/IB2017/056874 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, International Filing Date: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, 03 November 2017 (03.11.2017) DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, English KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, Publication Language: English MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, Priority Data: SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, 1618532.4 03 November 2016 (03.11.2016) GB TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. 62/541,133 04 August 2017 (04.08.2017) US (84) Designated States (unless otherwise indicated, for every Applicant: NOVARTIS AG [CH/CH]; Lichtstrasse 35, kind of regional protection available): ARIPO (BW, GH, 4056 Basel (CH). GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, Inventors: ROLLINS, Scott; c/o Tetherex Pharmaceuti-TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, cals Corporation, 840 Research Parkway, Suite 516, Okla-EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, homa City, Oklahoma 73104 (US). ROTHER, Russell; c/o MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, Tetherex Pharmaceuticals Corporation, 840 Reserch Park- TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, way, Suite 516, Oklahoma City, Oklahoma 73104 (US). KM, ML, MR, NE, SN, TD, TG). STOCKER, Jonathan; c/o Tetherex Pharmaceuticals Cor- poration, 840 Research Parkway, Suite 516, Oklahoma City, = = Title: TREATMENT REGIMENS A 100 - — ia c i , ' -- 0 80 — W _ ILI— c..) > • 0 — 4 — 3 20 — : The present invention relates or binding fragments thereof, for use in the treatment or prevention of such disorders. In particular, the invention relates to treatment or prevention of pain crises associated with sickle cell disease, and to anti-P- selectin antibodies or binding fragments for use in the treatment or prevention of pain crises associated with sickle cell disease. (54) ---- antibodies Figure 1 = = 5.0 mg/kg SeIG1, P=0.001 = _ 2.5 mg/kg SeIG1, P=0.136 = _ — Placebo = = = = — = 1-1 kin 71- M GC c:::: , (57) GC , 1 the 0 thereof, ei IIIIIIIIIIII 0 2 4 6 8 10 12 Time (months) to the treatment or prevention of P-selectin mediated disorders, and to anti-P-selectin C [Continued on next page] WO 2018/083645 Al MIDEDIMOMOIDEIREIDIONIMMOHNIMOINVOIS Declarations under Rule 4.17: — as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(11)) — as to the applicant's entitlement to earlier application (Rule 4.17(iii)) claim the priority of the Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in amendments (Rule 48.2(h)) the event of receipt of